AU2023285400A1 — Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
Assigned to Zydus Lifesciences Ltd · Expires 2024-12-05 · 1y expired
What this patent protects
The aim of the invention is to provide liquid composition of Semaglutide with phenol in concentration of 0.11% w/w to 0.5% w/w which will enhance stability of the composition. Also provided herein a process for the preparation of composition of Semaglutide and method of using the…
USPTO Abstract
The aim of the invention is to provide liquid composition of Semaglutide with phenol in concentration of 0.11% w/w to 0.5% w/w which will enhance stability of the composition. Also provided herein a process for the preparation of composition of Semaglutide and method of using the same for treating diabetes and obesity.
Drugs covered by this patent
- Ozempic (semaglutide) · Novo Nordisk
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.